Clinical Trial Update: Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27 [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating how different doses of clopidogrel affect platelet inhibition in patients with BMI ≥ 27; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Les Laboratoires des Médicaments Stériles | Conditions: Cardiovascular Disease, Overweight | Phase 4 | Status: COMPLETED